FDA Rejects Liver Cancer Drug Combination Over Manufacturing Issues

The U.S. Food and Drug Administration has withheld approval for the combination therapy of rivoceranib and camrelizumab for hepatocellular carcinoma. This decision stems from identified deficiencies in manufacturing practices at a production site, not from concerns regarding the treatment's clinical effectiveness or safety data. The developers will need to address these issues before resubmitting for approval.